Scarica l'app Stockscreener
1.79
0.00%
0.00
Dopo l'orario di chiusura:
1.77
-0.02
-1.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ocugen Inc Borsa (OCGN) Ultime notizie
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress - Yahoo Finance
Ocugen, Inc. (OCGN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell - marketbeat.com
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com
Ocugen (OCGN) has a healthy cash position for 2026 - MSN
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com
Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares - Stock Titan
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - Bitget
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - Investing.com Australia
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
$Ocugen (OCGN.US)$ - Moomoo
Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | Ocugen, Inc. - Ocugen, Inc.
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Ocugen (OCGN) Completes Dosing in Key Clinical Trial for Stargar - GuruFocus
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease - MarketScreener
Ocugen completes enrollment in Stargardt disease gene therapy trial - Investing.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - ChartMill
Block Trades: What is the next catalyst for Ocugen IncEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden - Traders Union
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN PE Ratio & Valuation, Is OCGN Overvalued - Intellectia AI
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data - insidermonkey.com
Ocugen, Inc. (NASDAQ:OCGN) Q3 2025 Earnings Call Transcript - msn.com
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Retinal specialists drive clinical progress on modifier gene therapy, Ocugen, Inc. asserts - Traders Union
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - msn.com
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Risk Recap: Is Ocugen Inc undervalued by DCF analysisMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations - Yahoo Finance
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood - Insider Monkey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (OCGN) disaggregates holdings; reports 0% ownership in Ocugen - Stock Titan
Can Ocugen succeed where other gene therapy makers have struggled? - Pharma Voice
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies - TipRanks
What is Noble Financial's Estimate for Ocugen Q3 Earnings? - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen Earnings - MarketBeat
Ocugen posts investor presentation outlining progress across three gene-therapy BLAs, Phase 3 enrollment and positive Phase 2/3 data - TradingView
Ocugen (OCGN) showcases retinal gene therapy pipeline with new OCU410 Phase 2 data - Stock Titan
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital - MarketBeat
Ocugen (OCGN) Stock Maintained at Buy Rating by Chardan Capital - GuruFocus
Ocugen Shares Drop as Eye Disease Gene Therapy Shows Delays in Phase II Trial - Bitget
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study - The Globe and Mail
Noble Capital raises Ocugen stock price target on phase 2 results By Investing.com - Investing.com Australia
Noble Capital raises Ocugen stock price target on phase 2 results - Investing.com UK
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):